title: First Multicenter, Randomized Phase 3 Study in Patients  (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell  Lymphoma (PTCL): Alisertib (MLN8237) Versus  Investigator’s Choice (LUMIERE trial; NCT01482962).
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D064096:Aurora Kinase A / Q000037:antagonists & inhibitors*; D001381:Azepines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001381:Azepines; C550258:MLN 8237; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D064096:Aurora Kinase A